证券记录 · 已归档季度
RARE
Ultragenyx Pharmaceutical Inc. · Healthcare · Biotechnology
18被追踪持有人
-1Δ持有人
33.50M持有股份
$1.22B报告持仓市值
+0新建仓位
−1清仓
动量输入（同类管理人）：
持有人广度 -5.3% ·
股份流向 -7.7% ·
净新建仓位 -5.6%
· 公式
广泛减持：持股数量下降，持有人数量减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 477.97K | $7.18M | +1 | −2 |
| Q2 2026 | 97 | -6 | 59.88M | $1.99B | +8 | −14 |
| Q1 2026 | 106 | +4 | 55.54M | $1.16B | +10 | −7 |
| Q4 2025 | 102 | 0 | 62.50M | $1.44B | +1 | n/a |
| Q3 2025 | 19 | -1 | 45.29M | $1.36B | n/a | −2 |
| Q2 2025 | 18 | -1 | 33.50M | $1.22B | n/a | −1 |
| Q1 2025 | 16 | 0 | 17.22M | $623.52M | n/a | n/a |
| Q4 2024 | 16 | +1 | 16.41M | $690.18M | +1 | n/a |
| Q3 2024 | 14 | +2 | 15.84M | $879.45M | +2 | n/a |
| Q2 2024 | 12 | n/a | 15.75M | $647.24M | n/a | n/a |
持有人 · Q2 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (被动) | 10.21M | n/a | $371.36M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (被动) | 6.26M | n/a | $227.47M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 3 | T. Rowe Price ✦ | 2.89M | -10.3% | $104.95M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 4 | Fidelity (FMR) ✦ | 2.60M | n/a | $94.70M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 5 | State Street Global Advisors ✦ (被动) | 2.57M | -1.8% | $93.53M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.87M | -23.6% | $68.06M | 0.0% | ▼ Trim | 5 | SEC ↗ ×6 |
| 7 | Geode Capital Management ✦ (被动) | 1.71M | +4.0% | $62.29M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Adage Capital Partners ✦ | 1.53M | -28.8% | $55.61M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 9 | Norges Bank ✦ (被动) | 983.64K | 0.0% | $35.77M | 0.0% | Held | 5 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 576.90K | -8.9% | $20.98M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 540.80K | -2.8% | $19.66M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 12 | Point72 Asset Management ✦ | 515.97K | -47.1% | $18.76M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Millennium Management ✦ | 486.34K | -31.7% | $17.68M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 252.33K | +174.1% | $9.17M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 15 | Renaissance Technologies ✦ | 208.30K | -30.5% | $7.57M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | Fisher Asset Management ✦ | 185.76K | -10.6% | $6.75M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Marshall Wace ✦ | 65.87K | -80.3% | $2.40M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 37.63K | -85.3% | $1.37M | 0.0% | ▼ Trim | 5 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Duquesne Family Office | $3.09M | 曾为 0.1% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 293 持有人, 97.86M 股份, $1.96B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 15
Horn Howard
Officer · 7.07K 股 · $107,898
Sep 15
Huizenga Theodore Alan
Officer · 1.28K 股 · $17,410
Sep 03
Huizenga Theodore Alan
Officer · 161 股 · $2,252
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Oct 20
SC 13G: Madison Avenue Partners, LP
Aug 14
SC 13G: RTW INVESTMENTS, LP
Aug 13
SC 13G: AQR CAPITAL MANAGEMENT LLC
Aug 07
SC 13G: STATE STREET CORP
Jul 31
SC 13G: VANGUARD CAPITAL MANAGEMENT LLC
Jul 31
SC 13G/A: VANGUARD PORTFOLIO MANAGEMENT LLC
Jul 30
SC 13G/A: BlackRock, Inc.
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2025 ·
方法论 ·
通过API获取此数据